NKTR insider filings
NEKTAR THERAPEUTICS — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-25. Screen NKTR transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 9 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings by 2 insiders — 604 shares, $43,476 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: sale of 418 shares @ $71.98 ($30,088) by ROBIN HOWARD W, filed 2026-08-20.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ROBIN HOWARD W — President & CEO, Director | 2 | — | 1 leg · 418 sh · $30,088 | 1 |
| Zalevsky Jonathan — Chief R&D Officer | 2 | — | 1 leg · 186 sh · $13,388 | 1 |
| Ajer Jeffrey Robert — Director | 1 | — | — | 2 |
| Brainard Diana — Director | 1 | — | — | 2 |
| CHESS ROBERT — Director | 1 | — | — | 2 |
| GREER R SCOTT — Director | 1 | — | — | 2 |
| WHITFIELD ROY A — Director | 1 | — | — | 2 |
Recent insider filings — NEKTAR THERAPEUTICS
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-25 | 4 | WHITFIELD ROY A — Director | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-09-25 | 4 | GREER R SCOTT — Director | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-09-25 | 4 | CHESS ROBERT — Director | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-09-25 | 4 | Ajer Jeffrey Robert — Director | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-09-25 | 4 | Brainard Diana — Director | Grant/award (A): 2,000 @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 186 @ $71.98 | EDGAR |
| 2026-08-20 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 418 @ $71.98 | EDGAR |
| 2026-07-24 | 4 | ROBIN HOWARD W — President & CEO, Director | Grant/award (A): 57,200 (derivative) @ $0 | EDGAR |
| 2026-07-24 | 4 | Zalevsky Jonathan — Chief R&D Officer | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 5,681 @ $70 | EDGAR |
| 2026-06-18 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 5,303 @ $59.97 · Sale (S): 4,697 @ $60.71 · Sale (S): 5,500 @ $60.81 · Sale (S): 4,500 @ $61.65 | EDGAR |
| 2026-06-17 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 5,538 @ $60.71 | EDGAR |
| 2026-05-21 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 199 @ $65.51 | EDGAR |
| 2026-05-21 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 444 @ $65.51 | EDGAR |
| 2026-02-20 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 180 @ $73 | EDGAR |
| 2026-02-20 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 423 @ $73 | EDGAR |
| 2026-01-22 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 3,867 @ $35.67 | EDGAR |
| 2025-12-23 | 4 | Zalevsky Jonathan — Chief R&D Officer | Grant/award (A): 6,250 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | ROBIN HOWARD W — President & CEO, Director | Grant/award (A): 21,667 @ $0 · Grant/award (A): 86,667 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Wilson Mark Andrew — Chief Legal Officer | Grant/award (A): 1,903 @ $0 · Sale (S): 630 @ $54.28 · Grant/award (A): 3,400 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | Zalevsky Jonathan — Chief R&D Officer | Grant/award (A): 2,666 @ $0 · Sale (S): 1,157 @ $54.28 · Grant/award (A): 4,766 (derivative) @ $0 | EDGAR |
| 2025-11-25 | 4 | ROBIN HOWARD W — President & CEO, Director | Grant/award (A): 7,110 @ $0 · Sale (S): 2,207 @ $54.28 · Grant/award (A): 12,170 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | WHITFIELD ROY A — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | Brainard Diana — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | Ajer Jeffrey Robert — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | CHESS ROBERT — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | GREER R SCOTT — Director | Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
| 2025-09-11 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 2,100 @ $45.16 · Sale (S): 1,200 @ $46.41 · Sale (S): 2,156 @ $47.49 · Sale (S): 1,210 @ $48.18 | EDGAR |
| 2025-09-08 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 793 @ $32.43 · Sale (S): 432 @ $33.60 · Sale (S): 189 @ $34.41 · Sale (S): 307 @ $35.69 | EDGAR |
| 2025-09-08 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 1,923 @ $32.37 · Sale (S): 1,496 @ $33.54 · Sale (S): 613 @ $34.40 · Sale (S): 1,134 @ $35.80 · Sale (S): 3,304 @ $37.87 · Sale (S): 2,226 @ $38.82 · +1 more | EDGAR |
| 2025-09-04 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 485 @ $30.10 | EDGAR |
| 2025-09-04 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 1,500 @ $30.16 | EDGAR |
| 2025-08-21 | 4 | Wilson Mark Andrew — Chief Legal Officer | Sale (S): 676 @ $26.59 · Grant/award (A): 21,666 (derivative) @ $0 | EDGAR |
| 2025-08-21 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 725 @ $26.59 · Grant/award (A): 16,666 (derivative) @ $0 | EDGAR |
| 2025-08-21 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 1,573 @ $26.59 · Grant/award (A): 86,666 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Wilson Mark Andrew — Chief Legal Officer | Sale (S): 9,996 @ $0.67 | EDGAR |
| 2025-05-21 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 10,712 @ $0.67 | EDGAR |
| 2025-05-21 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 23,208 @ $0.67 | EDGAR |
| 2025-02-21 | 4 | Wilson Mark Andrew — Chief Legal Officer | Sale (S): 11,040 @ $1.01 | EDGAR |
| 2025-02-21 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 10,300 @ $1.01 | EDGAR |
| 2025-02-21 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 23,774 @ $1.01 | EDGAR |
| 2024-12-26 | 4 | Wilson Mark Andrew — Chief Legal Officer | Sale (S): 33,402 @ $0.90 · Sale (S): 16,560 @ $0.89 | EDGAR |
| 2024-12-20 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 51,115 @ $0.94 | EDGAR |
| 2024-12-19 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 46,995 @ $1.01 · Sale (S): 85,035 @ $0.99 | EDGAR |
| 2024-12-17 | 4 | Wilson Mark Andrew — Chief Legal Officer | Grant/award (A): 165,938 @ $0 · Grant/award (A): 331,875 (derivative) @ $0 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | Zalevsky Jonathan — Chief R&D Officer | Grant/award (A): 135,000 @ $0 · Grant/award (A): 270,000 (derivative) @ $0 · Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | ROBIN HOWARD W — President & CEO, Director | Grant/award (A): 410,625 @ $0 · Grant/award (A): 821,250 (derivative) @ $0 · Grant/award (A): 1,300,000 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | Wilson Mark Andrew — Chief Legal Officer | Sale (S): 6,407 @ $1.01 | EDGAR |
| 2024-11-20 | 4 | Zalevsky Jonathan — Chief R&D Officer | Sale (S): 7,785 @ $1.01 | EDGAR |
| 2024-11-20 | 4 | ROBIN HOWARD W — President & CEO, Director | Sale (S): 16,278 @ $1.01 | EDGAR |
Recent 8-K events — NEKTAR THERAPEUTICS
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-25 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-20 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NKTR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →